Picture EBD Group BioTech Showcase 2020 San Francisco BEU2020 650x76px
Document › Details

IFM Therapeutics. (6/22/16). "Press Relase: IFM Therapeutics Raises $27 Million Series A Financing Led by Atlas Venture and Abingworth". Cambridge, MA.

Organisations Organisation IFM Therapeutics (US, acquired 8/17 by BMS)
  Today Bristol-Myers Squibb Co. (BMS) (NYSE: BMY)
  Group Bristol-Myers Squibb (BMS) (Group)
  Organisation 2 Atlas Venture (Group)
Products Product immunotherapy
  Product 2 venture capital
Index terms Index term IFM Therapeutics–SEVERAL: investment, 201606 financing round Series A $27m led by Atlas Venture + Abingworth + incl Novartis
  Index term 2 IFM Therapeutics–Novartis: investment, 201606 financing round Series A totalling $27m incl co-investor Novartis
Persons Person Formela, Jean-François (Atlas Venture 201205 Partner joined 1993 before Schering-Plough)
  Person 2 Miles, Vincent J. (Vin) (Abingworth 201407– Partner joined 2007 before Alnylam + Millennium Pharmaceuticals)

First-in-class immune-modulators for cancer and inflammatory diseases

IFM Therapeutics, a biopharmaceutical company developing a portfolio of first-in-class small molecules targeting the innate immune system, today announced the closing of a $27 million Series A financing led by Atlas Venture and Abingworth, with participation from Novartis. In conjunction with the funding Jean-François Formela and Vincent Miles, Partners at Atlas and Abingworth respectively, have joined IFM’s CEO, Gary D. Glick, on the board of directors, with Dr. Formela serving as chair of the board.

IFM Therapeutics, incubated as a part of the Atlas Venture seed program, is developing modulators of novel targets that either enhance innate immune responses for treating cancer, or dampen certain immune responses that drive many inflammatory diseases. The company will use the proceeds of the financing to advance and expand its early-stage portfolio and begin clinical development of its most advanced product candidate, a selective activator of a novel target, for treating solid tumors.

“While proteins in the innate immune system represent an attractive landscape of therapeutic targets, they have been notoriously difficult to drug,” said Dr. Formela from Atlas. “During the brief period since its founding, IFM has made excellent progress on several of these targets, reflecting its exceptional team of experienced scientists and executives, possessing expertise in medicinal chemistry, a deep understanding of the relevant biology, and relationships with academic thought leaders in the areas of immunology and immune oncology.”

“IFM’s programs have the potential to make a major difference in the lives of patients with serious, and sometimes fatal, diseases,” said Abingworth’s Dr. Miles. “We look forward to helping the team build on their strong start to advance these programs into clinical development.”

“This financing is an important validation of the IFM team and technology,” said Dr. Glick, IFM’s Co-founder and CEO. “The company is fortunate to be working with a talented and experienced group of investors. Their expertise in building world-class biopharmaceutical companies will be invaluable as we grow the company.”

About Atlas Venture

Atlas Venture is a biotech-focused, early-stage venture capital firm that creates and invests in life sciences startup companies in the U.S. Atlas is based in Cambridge, Massachusetts. Since 1993, Atlas has invested in over 150 early stage life sciences companies. For more information, visit

About Abingworth

Abingworth is an international investment group dedicated to collaborating with life sciences entrepreneurs to develop their ideas into products that have a dramatic impact on health. With over $1.1 billion under management, Abingworth invests at all stages of development, from start-ups to publicly traded companies, and across all life science sectors. Supporting its portfolio companies with a team of 27 at offices in London, Menlo Park (California) and Boston, Abingworth has invested in 140 life science companies, leading to 62 IPOs and 40 mergers and acquisitions. For more information, visit

Media Contact

Amanda Sellers
Spectrum Science Communications

Record changed: 2017-08-05


Picture [LSA] – The Business Web Portal 650x89px

More documents for Bristol-Myers Squibb (BMS) (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group BioTech Showcase 2020 San Francisco BEU2020 650x76px

» top